Dr. Love has a long and distinguished career in the biopharmaceutical industry. He most recently served as president and CEO of Global Blood Therapeutics (GBT), a biotech company founded in 2011 to address sickle cell disease. Dr. Love led GBT’s growth from a pre-clinical start-up into a multi-national commercial business and introduced the first innovative rationally designed, disease-modifying treatment for sickle cell disease. GBT
was acquired by Pfizer for $5.8 billion in October 2022.
In addition to his ongoing commitment to the sickle cell disease community, Dr. Love
serves on the boards of directors of Gilead Sciences, Structure Therapeutics, Royalty Pharma plc. and several early-stage biotechs. He is also vice chair of the board of the Biotechnology Innovation Organization (BIO) and a founding board member of Life Science Cares Bay Area. Before GBT, he served as executive vice president, of research and development and technical operations, at Onyx Pharmaceuticals, Inc., where he played an instrumental role in initiating and completing Onyx’s first Phase 3 clinical trials, and the approval of Kyprolis. Onyx was purchased by Amgen for $10.4 billion. Prior to Onyx, he served as president, chief executive officer and chairman of Nuvelo, Inc., and before that as senior vice president, development, at Theravance, Inc. Dr. Love began his biotech career at Genentech where he held senior management positions in medical affairs and product development, and he served as chairman of Genentech’s Product Development Committee. As vice president of product development, Dr. Love oversaw the development and approval of multiple innovative therapies including Rituxan, Herceptin, Avastin, Xolair, and Tenecteplase.
Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.